Go Premium in Our Biggest Sale Ever

Go Ultimate 75% OFF

HK:1530 Stock Latest News

RatingsAnalyst Initiates Buy on 3SBio, Seeing Upside to HKD17.8 Target Price Driven by Robust Pipeline and Licensing Growth3w ago

RatingsJill Wu Maintains Buy on Long-Term 707 Growth, Slightly Lowering Target Price to HK$34.78 Amid Near-Term Headwinds2M ago
Company Announcements3SBio Delivers Modest Revenue Growth but Lower Headline Profit in First Half 20262M ago
Company Announcements3SBio Board to Review 2026 Interim Results and Consider Dividend3M ago
Company Announcements3SBio Shareholders Approve Dividend and Auditor Change at AGM4M ago

3SBio Sets June 2026 AGM to Approve Dividend, New Auditor and Share Issue Mandate

Company Announcements3SBio Sets June 2026 AGM to Approve Dividend, New Auditor and Share Issue Mandate5M ago

Company Announcements3SBio Moves to Replace Long-Standing Auditor EY With KPMG at 2026 AGM5M ago

Company Announcements3SBio Shareholders Back Spin-Off Dividend of Mandi Inc. Shares6M ago

Company Announcements3SBio Calls Extraordinary Meeting to Approve Mandi Spin-Off Dividend7M ago
Company Announcements3SBio Proposes HKD 0.25 Final Dividend for 2025 Financial Year7M ago
Company Announcements3SBio Plans Conditional Spin-Off Dividend via Mandi Inc. Share Distribution7M ago
Company Announcements3SBio Nearly Doubles Revenue and Quadruples Profit in 2025, Keeps Dividend Steady7M ago

3SBio Sets March Board Meeting to Approve 2025 Results and Weigh Mandi Spin-Off Payout

Company Announcements3SBio Sets March Board Meeting to Approve 2025 Results and Weigh Mandi Spin-Off Payout8M ago

Company Announcements3SBio Completes Share Placement to Boost R&D and Global Expansion11M ago

Company Announcements3SBio Announces Strategic Share Placement to Raise HK$3 Billion11M ago

Company Announcements3SBio Announces Proposed Spin-Off and Listing of Mandi Inc.11M ago
Company Announcements3SBio Subsidiary Mandi Inc. Issues Shares Under Equity Incentive Plan1y ago
Ratings3SBio’s Strategic Alliance with Pfizer and Promising Growth Potential Justify Buy Rating1y ago
Ratings3SBio’s Promising Future: Buy Rating Backed by Financial Gains and Innovative Drug Pipeline1y ago

3SBio, Inc. Reports Strong Net Profit Growth

Company Announcements3SBio, Inc. Reports Strong Net Profit Growth1y ago

Company Announcements3SBio Reports Increased Profits Despite Revenue Dip in H1 20251y ago

Company Announcements3SBio Inc. Schedules Board Meeting to Review Interim Results and Dividend1y ago